Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HSPA9 | P38646 | 2/20 | 0.49 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | SNCA | P37840 | 4/20 | 0.42 |
| ▸ | TDP2 | O95551 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | PNMT | P11086 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL429310 | 0.87 | MAPT (0.57) | MAPTNPC1RAB9AMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL4967505 | 0.85 | MAPT (0.56) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL6540296 | 0.84 | PGR (0.62) | MAPTNPC1RAB9ATDP2TDP1 | |
| SCHEMBL16150263 | 0.82 | MAPT (0.49) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL2060732 | 0.81 | HSPA9 (0.57) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL28332254 | 0.79 | PNMT (0.54) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL25172680 | 0.78 | MAPT (0.46) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL8314094 | 0.78 | TDP2 (0.50) | MAPTMEN1KMT2ACAPN9CASP3 | |
| SCHEMBL445340 | 0.76 | CYP3A4 (0.53) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL2636968 | 0.76 | MAPT (0.54) | MAPTNPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103180294-B | Diamines, polyimide precursor, polyimide, liquid crystal aligning agent, liquid crystal orientation film and liquid crystal display device | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-09-23 | — | — | CN | disclosed |
| CN-103180294-A | Diamine, polyimide precursor, polyimide, liquid-crystal alignment material, liquid-crystal alignment film, and liquid-crystal display element | NISSAN CHEMICAL IND LTD | 2013-06-26 | — | — | CN | disclosed |
| US-8377961-B2 | Cyclic-alkylamine derivatives as inhibitors of the interaction between MDM2 and P53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-19 | — | — | US | disclosed |
| US-20120071508-A1 | CYCLIC-ALKYLAMINE DERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | LACRAMPE JEAN FERNAND ARMAND (FR) | 2012-03-22 | — | — | US | disclosed |
| US-8088795-B2 | Cyclic-alkylamine derivatives as inhibitors of the interaction between MDM2 and p53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-01-03 | — | — | US | disclosed |
| EP-1919920-B1 | PENTACYCLIC KINASE INHIBITORS | GENENTECH INC (US) | 2011-05-18 | — | — | EP | disclosed |
| US-7749994-B2 | Pentacyclic kinase inhibitors | GENENTECH, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7749994-B2 | Pentacyclic kinase inhibitors | GENENTECH, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20100168163-A1 | CYCLIC-ALKYLAMINE DERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICAL N.V. (BE) | 2010-07-01 | — | — | US | disclosed |
| EP-1999126-B1 | CYCLIC-ALKYLAMINEDERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA NV (BE) | 2010-06-09 | — | — | EP | disclosed |
| WO-2007022102-A2 | PENTACYCLIC KINASE INHIBITORS | GENENTECH, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037791-A1 | serine/threonine kinase inhibitors, useful for therapy and/or prophylaxis of cancers in mammals | HOFFMAN-LAROUCHE, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070037791-A1 | serine/threonine kinase inhibitors, useful for therapy and/or prophylaxis of cancers in mammals | HOFFMAN-LAROUCHE, INC. | 2007-02-15 | — | — | US | disclosed |
| EP-1678173-A2 | 4-HETEROBICYCLYLAMINO-SUBSTITUTED QUINAZOLINES AND ANALOGUES THEREOF AS CAPSAICIN-ANTAGONISTS | NEUROGEN CORPORATION (US) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005023807-A2 | 4 - HETEROBICYCLYAMINO - SUBSTITUTED QUINAZOLINES AND ANALOGUES THEROF AS CAPSAICIN - ANTAGONISTS | NEUROGEN CORPORATION (US) | 2005-03-17 | — | — | WO | disclosed |
| US-5968725-A | MATERIAL COMPRISING ON SUPPORT SILVER HALIDE PHOTOSENSITIVE LAYER CONTAINING ORGANIC SILVER SALT, REDUCING AGENT, ULTRAHIGH CONTRAST PROMOTING AGENT, SELECTED HETEROCYCLIC MERCAPTO COMPOUND | FUJI PHOTO FILM CO., LTD. (JP) | 1999-10-19 | — | — | US | disclosed |
| US-5236807-A | Negative, hydrazine compound | FUJI PHOTO FILM CO., LTD. (JP) | 1993-08-17 | — | — | US | disclosed |
| US-4769316-A | Method for restraining the formation of re-reversal negative image in direct positive silver halide photographic materials | FUJI PHOTO FILM CO., LTD. (JP) | 1988-09-06 | — | — | US | disclosed |
| US-4607006-A | Silver halide photographic light-sensitive material containing non-spectral sensitizing electron donative silver halide adsorptive compound | FUJI PHOTO FILM CO., LTD. (JP) | 1986-08-19 | — | — | US | disclosed |
| US-3935199-A | ANALEPTIC | MEAD JOHNSON & COMPANY (US) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071508-A1 | CYCLIC-ALKYLAMINE DERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | TP53, MDM2, TP53BP1 | MAPT 2131/4885NPC1 3334/4885RAB9A 3532/4885 |
| US-20070037791-A1 | serine/threonine kinase inhibitors, useful for therapy and/or prophylaxis of cancers in mammals | RAF1, CHEK1, BRAF | MAPT 3710/4885NPC1 4211/4885RAB9A 1297/4885 |
| US-20100168163-A1 | CYCLIC-ALKYLAMINE DERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | TP53, MDM2, TP53BP1 | MAPT 2131/4885NPC1 3334/4885RAB9A 3532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.